New York, April 29, 2024 - PRISM MarketView - Surgical robotic technology company, SS Innovations International (OTC: SSII), has achieved a key milestone in pediatric surgery as the company announced on Monday that its flagship SSi Mantra surgical robotic system has been utilized to perform the first pyeloplasty procedure on an infant. The SSi Mantra has now been used in more than 1000 procedures, including cardiothoracic, head and neck, gynecology, urology and general surgeries.
The successful surgery was performed on a 12 month old baby weighing 8.5 kilograms (~17.6 pounds). by Dr. Chandra Mohan Vaddi at the Preeti Urology & Kidney Hospital in Hyderabad, India.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations stated that the surgical milestone is a testament to the precision and adaptability of the SSi Mantra in meeting the nuanced requirements of pediatric care.
“It underscores our commitment to extending state-of-the-art surgical options to all patient demographics, including the most vulnerable. From the very beginning, our vision for our surgical robotic system was to revolutionize healthcare for everyone, including children, ensuring that even the most delicate surgeries are performed with unmatched precision and care. Words can hardly express the overwhelming joy and pride we feel as we witness the SSi Mantra Surgical Robotic System changing the trajectory of children’s lives.”
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer
SSi Mantra Surgical Robotic System
The SSi Mantra Surgical Robotic System has been granted regulatory approval in India, Guatemala and Indonesia, and is clinically validated in more than 60 different types of surgical procedures. SS Innovations has commenced the regulatory approval process in the United States and European Union, and anticipates receiving approvals in the latter half of 2024 or 2025.
About SS Innovations International, Inc.
SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra”, its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at ssinnovations.com or LinkedIn for updates.
SS Innovations International (OTC: SSII) is featured on PRISM Emerging MedDevices Index
About PRISM MarketView
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities
PRISM MarketView - Social Media (X)